377 related articles for article (PubMed ID: 25783402)
1. Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Interiano RB; McCarville MB; Wu J; Davidoff AM; Sandoval J; Navid F
J Pediatr Surg; 2015 Sep; 50(9):1484-9. PubMed ID: 25783402
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Kim A; Widemann BC; Krailo M; Jayaprakash N; Fox E; Weigel B; Blaney SM
Pediatr Blood Cancer; 2015 Sep; 62(9):1562-6. PubMed ID: 26207356
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.
Bond M; Bernstein ML; Pappo A; Schultz KR; Krailo M; Blaney SM; Adamson PC
Pediatr Blood Cancer; 2008 Feb; 50(2):254-8. PubMed ID: 17262795
[TBL] [Abstract][Full Text] [Related]
4. Compassionate use of bevacizumab (Avastin) in children and young adults with refractory or recurrent solid tumors.
Benesch M; Windelberg M; Sauseng W; Witt V; Fleischhack G; Lackner H; Gadner H; Bode U; Urban C
Ann Oncol; 2008 Apr; 19(4):807-13. PubMed ID: 18056650
[TBL] [Abstract][Full Text] [Related]
5. Phase I expansion cohort to evaluate the combination of bevacizumab, sorafenib and low-dose cyclophosphamide in children and young adults with refractory or recurrent solid tumours.
Federico SM; Caldwell KJ; McCarville MB; Daryani VM; Stewart CF; Mao S; Wu J; Davidoff AM; Santana VM; Furman WL; Pappo AS; Navid F
Eur J Cancer; 2020 Jun; 132():35-42. PubMed ID: 32325418
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study.
Saylors RL; Stine KC; Sullivan J; Kepner JL; Wall DA; Bernstein ML; Harris MB; Hayashi R; Vietti TJ;
J Clin Oncol; 2001 Aug; 19(15):3463-9. PubMed ID: 11481351
[TBL] [Abstract][Full Text] [Related]
7. Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
Lombardi G; Zustovich F; Farina P; Fiduccia P; Della Puppa A; Polo V; Bertorelle R; Gardiman MP; Banzato A; Ciccarino P; Denaro L; Zagonel V
Anticancer Drugs; 2013 Jan; 24(1):90-7. PubMed ID: 23075631
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults.
Bodea J; Caldwell KJ; Federico SM
Front Oncol; 2022; 12():864790. PubMed ID: 35692751
[TBL] [Abstract][Full Text] [Related]
9. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Mahalingam D; Malik L; Beeram M; Rodon J; Sankhala K; Mita A; Benjamin D; Ketchum N; Michalek J; Tolcher A; Wright J; Sarantopoulos J
Cancer Chemother Pharmacol; 2014 Jul; 74(1):77-84. PubMed ID: 24817603
[TBL] [Abstract][Full Text] [Related]
10. Influence of Sorafenib and Bevacizumab on pancreatic volume - A monocentric CT based analysis.
Phillip V; Zahel T; Bärtl K; Rasch S; Ebert O; Schmid RM; Rummeny E; Algül H
Pancreatology; 2016; 16(4):621-4. PubMed ID: 26968257
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
Ara M; Pastushenko E
Actas Dermosifiliogr; 2014 Dec; 105(10):900-12. PubMed ID: 24766821
[TBL] [Abstract][Full Text] [Related]
12. Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Falchook GS; Wheler JJ; Naing A; Piha-Paul SA; Fu S; Tsimberidou AM; Hong DS; Janku F; Zinner R; Jiang Y; Huang M; Lin Q; Parkhurst K; Kurzrock R
Invest New Drugs; 2015 Feb; 33(1):215-24. PubMed ID: 25363205
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced secondary pneumothorax.
Bazan F; Vollmer I; Gayete A
Arch Bronconeumol; 2014 Jan; 50(1):44. PubMed ID: 24119689
[No Abstract] [Full Text] [Related]
14. Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Yılmaz S; Özçakar ZB; Taktak A; Kiremitçi S; Ensari A; Dinçaslan H; Yalçınkaya F
Pediatr Nephrol; 2016 Jun; 31(6):1029-32. PubMed ID: 26928310
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
[TBL] [Abstract][Full Text] [Related]
16. Response of refractory Ewing sarcoma to pazopanib.
Alcindor T
Acta Oncol; 2015 Jul; 54(7):1063-4. PubMed ID: 25345493
[No Abstract] [Full Text] [Related]
17. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
Wagner L; Turpin B; Nagarajan R; Weiss B; Cripe T; Geller J
Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of imetelstat in children with refractory or recurrent solid tumors: a Children's Oncology Group Phase I Consortium Study (ADVL1112).
Thompson PA; Drissi R; Muscal JA; Panditharatna E; Fouladi M; Ingle AM; Ahern CH; Reid JM; Lin T; Weigel BJ; Blaney SM
Clin Cancer Res; 2013 Dec; 19(23):6578-84. PubMed ID: 24097866
[TBL] [Abstract][Full Text] [Related]
19. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).
Longhi A; Ferrari S; Tamburini A; Luksch R; Fagioli F; Bacci G; Ferrari C
Cancer; 2012 Oct; 118(20):5050-9. PubMed ID: 22415578
[TBL] [Abstract][Full Text] [Related]
20. The clinical outcome of pazopanib treatment in Japanese patients with relapsed soft tissue sarcoma: A Japanese Musculoskeletal Oncology Group (JMOG) study.
Nakamura T; Matsumine A; Kawai A; Araki N; Goto T; Yonemoto T; Sugiura H; Nishida Y; Hiraga H; Honoki K; Yasuda T; Boku S; Sudo A; Ueda T
Cancer; 2016 May; 122(9):1408-16. PubMed ID: 26970174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
